GLP-1 Drugs Reshape Healthcare: Insurers Battle Over Coverage Costs

New weight-loss medications are changing how we treat obesity, but they are also causing massive financial tension across the medical system. Employers, health insurance companies, and pharmaceutical giants are currently locked in a fierce battle over who will foot the bill for these highly effective, yet incredibly expensive, treatments.

The Financial Shockwave of New Weight-Loss Drugs

Medications known as GLP-1 receptor agonists have completely disrupted the traditional approach to obesity. Originally developed to treat Type 2 diabetes, these drugs mimic a hormone that targets areas of the brain regulating appetite and food intake. The clinical results have been staggering, with patients routinely losing 15 to 20 percent of their body weight.

However, the cost of these treatments is putting unprecedented strain on healthcare budgets. Novo Nordisk prices its blockbuster weight-loss drug Wegovy at a list price of $1,349 for a one-month supply. Rival pharmaceutical company Eli Lilly prices its competing drug Zepbound at $1,059 per month.

When you consider that over 100 million adults in the United States qualify as obese based on their Body Mass Index (BMI), the math quickly becomes unsustainable for insurance providers. If Medicare and private insurers covered these drugs for everyone who medically qualifies, the annual cost would easily exceed hundreds of billions of dollars. This reality has forced insurers to draw hard lines in the sand regarding what they will and will not pay for.

Employers Hit the Brakes on Coverage

Most Americans get their health insurance through their employers. Company executives want their workforce to be healthy, but the sudden spike in pharmacy claims tied to GLP-1 drugs has caught many businesses off guard. Adding coverage for drugs like Wegovy and Zepbound can cause a company’s total healthcare spending to jump by millions of dollars in a single year.

Because of these soaring premiums, major employers are starting to pull the plug. In early 2024, the North Carolina State Health Plan voted to completely drop coverage of GLP-1 weight-loss drugs for its government workers and teachers. The board revealed that covering the medications was projected to cost the state program up to $1.5 billion by the end of the decade. Without dropping the coverage, they would have been forced to double the monthly insurance premiums for all state employees.

Private companies are following suit. The massive hospital network Ascension recently informed its employees that it would no longer cover anti-obesity medications under its staff health plan. Other major corporations are choosing a middle ground. Instead of banning the drugs outright, they are working with pharmacy benefit managers (PBMs) to place strict lifetime limits on the medications or cap the total amount the company will spend per employee.

How Insurers Are Restricting Access

Insurance companies use several distinct tactics to control costs and limit the number of patients receiving expensive GLP-1 prescriptions. If you try to get a prescription for one of these medications today, you will likely run into one of the following roadblocks.

Strict Prior Authorization

Doctors cannot simply write a prescription and send you to the pharmacy. Insurers now require mountains of paperwork, known as prior authorization, to prove the drug is medically necessary. They typically require a patient to have a BMI over 30, or a BMI over 27 paired with a weight-related health condition like high blood pressure or sleep apnea. Insurers also frequently demand proof that the patient has actively participated in a structured diet and exercise program for at least six months before they will approve the drug.

The Diabetes Divide

Insurers are fiercely strict about diagnosis codes. Drugs like Ozempic and Mounjaro contain the exact same active ingredients as Wegovy and Zepbound (semaglutide and tirzepatide, respectively). However, Ozempic and Mounjaro are FDA-approved strictly for Type 2 diabetes. Insurers will readily cover these drugs if a patient has an A1C blood sugar level of 6.5 or higher. If a patient does not have official diabetes paperwork, the insurance company will deny the claim, even if the patient is severely obese.

Step Therapy Protocols

Many health plans now force patients to undergo “step therapy.” This means an insurer will refuse to pay for a $1,000-a-month drug like Wegovy until the patient first tries and fails to lose weight on older, significantly cheaper medications. Patients are often required to spend months taking generic phentermine, Qsymia, or Contrave. Only if those cheaper options fail to produce results will the insurer consider covering a GLP-1 drug.

The Search for a Middle Ground

The current standoff cannot last forever. Pharmaceutical companies are feeling the pressure from insurers and are beginning to adjust their pricing models to maintain market share.

Recently, Eli Lilly announced a new direct-to-consumer option to help patients bypass insurance denials entirely. They released single-dose vials of Zepbound directly to patients paying out of pocket. By removing the expensive auto-injector pen from the manufacturing process, Eli Lilly is able to sell a month’s supply of the lower doses for $399 to $549. This is still a significant expense, but it represents a massive discount from the traditional $1,059 list price.

The ultimate question for the healthcare industry is whether the upfront cost of these drugs is worth the long-term savings. Advocates argue that curing obesity will drastically reduce future spending on heart bypass surgeries, knee replacements, and kidney dialysis. Insurers counter that because patients often regain the weight as soon as they stop taking the medication, GLP-1s represent a lifetime subscription cost that current healthcare budgets simply cannot support.

Frequently Asked Questions

What are GLP-1 drugs? GLP-1 drugs are a class of medications that mimic a naturally occurring hormone in the body. They stimulate insulin production, slow down digestion, and send signals to the brain that you are full. Popular brands include Ozempic, Wegovy, Mounjaro, and Zepbound.

Why won’t my insurance cover Wegovy or Zepbound? Many insurance plans classify weight-loss medications as “lifestyle” drugs rather than essential medical treatments. Furthermore, the high monthly cost of these specific medications (often over $1,000 per month) has caused many employers to explicitly exclude them from their health plan benefits to keep premium costs down.

How much do these weight-loss medications cost out of pocket? Without insurance coverage or manufacturer coupons, a one-month supply of Wegovy costs about $1,349. Zepbound has a list price of $1,059. However, Eli Lilly now offers a specific vial version of Zepbound directly to self-paying patients for between $399 and $549 a month.

Are Medicare and Medicaid covering these treatments? By law, Medicare is currently prohibited from covering drugs prescribed exclusively for weight loss. However, Medicare will cover Wegovy if it is specifically prescribed to reduce the risk of heart attacks and strokes in patients with existing cardiovascular disease. Medicaid coverage varies wildly by state, with only a handful of states currently covering GLP-1s for weight loss.